Fig. 3From: Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patientsNAbs titer in hospitalized COVID-19 patients at D1, D7, and D30 post-hospitalization and in convalescent plasma donors. COVID-19 patients with moderate (1a) (1b; oxygenation) or severe (2) disease (see Additional file 1: Table S2) along with convalescent plasma donors (PLS; see the “Methods” section) develop high titers of NAbs, yet with distinct per group kinetics, higher values, and duration. Shown indications are as in Fig. 1; the red arrow indicates the only patient that died because of COVID-19-related complicationsBack to article page